Margo Stevenson, DO
Allergy & Immunology · Sturbridge, MANPI 1053755611
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $64,854 of the $98,255 with a category attached, or 66.0%. Regeneron Healthcare Solutions, Inc. accounts for 85.7% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2023 at $35,123 and has fallen 99.1% since, to $324 in 2025. Among allergy & immunology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 756 payments — averaging $129.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$84K
- Sanofi$4K
- AstraZeneca$2K
- GSK$1K
- Novartis$1K
- Pfizer$947
- plus $4K from 22 others
What the payments were for
- Consulting fees$3,3093%
- Speaking & faculty fees$64,85466%
- Travel & lodging$14,96615%
- Food & beverage$14,96315%
- Education$1630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 182 | $84,227 |
| Sanofi | 62 | $4,417 |
| AstraZeneca | 98 | $2,275 |
| GSK | 70 | $1,178 |
| Novartis | 98 | $1,029 |
| Pfizer | 44 | $947 |
| AbbVie | 27 | $676 |
| CSL Behring | 24 | $511 |
| Amgen | 26 | $493 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $376 |
| Pharming Healthcare, Inc. | 13 | $307 |
| Boehringer Ingelheim | 15 | $251 |
| Aimmune Therapeutics, Inc. | 10 | $236 |
| Sanofi-aventis U.S. LLC | 9 | $173 |
| Kaleo, Inc. | 8 | $166 |
| Optinose US, Inc. | 9 | $159 |
| LEO Pharma Inc. | 6 | $138 |
| Teva Pharmaceuticals USA, Inc. | 8 | $130 |
| Covis Pharma GmbH | 6 | $126 |
| Grifols USA, LLC | 6 | $104 |
| Alk-abello, Inc | 3 | $88 |
| Biocryst US Sales Co., LLC | 4 | $77 |
| Shire North American Group Inc | 3 | $55 |
| Blueprint Medicines Corporation | 1 | $35 |
| USWM, LLC | 1 | $26 |
| Genentech USA, Inc. | 1 | $22 |
| Phadia US Inc. | 1 | $19 |
| Biocryst Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$98,255 in reported general payments places this provider in the 95th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 24 | $154,480 |
| Dupixent PenDupilumab | 14 | $97,096 |
| Dupixent SyringeDupilumab | 12 | $44,421 |
| Epinephrine | 24 | $5,859 |
| DuleraMometasone/Formoterol | 14 | $4,417 |
| Azelastine Hcl | 75 | $1,775 |
| Ipratropium Bromide | 48 | $1,308 |
| Montelukast Sodium | 31 | $554 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $362 |
| Mometasone Furoate | 12 | $203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $511 | $154,48024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in Sturbridge
- Wanda PhipatanakulBoston$679K
- Jonathan BayukNorthampton$420K
- Kathleen BuchheitBoston$224K
- Francisco BonillaLeominster$188K
- Aleena BanerjiBoston$133K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
- Maria CastellsGardner$65K
- Ami MehraChelmsford$64K
- David RobertsonSpringfield$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.